PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
Portfolio Pulse from Happy Mohamed
PhenomeX Inc. (NASDAQ:CELL) has announced that GSK will present data on the SpotLight Human Lambda reagent for the Beacon platform at the 16th annual Conference on Protein Expression in Animal Cells. The SpotLight reagents are used in cell line development productivity assays on the Beacon platform. The SpotLight Human Lambda reagent will be available for purchase after October 23, 2023.
September 21, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PhenomeX's announcement of the SpotLight Human Lambda reagent, which will be presented by GSK, could potentially boost the company's visibility and sales.
The announcement of a new product, especially one that will be presented by a major company like GSK, can increase visibility and potentially lead to increased sales. This could have a positive impact on PhenomeX's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100